Markets
MarketMind AI
Baskets
Alerts
F&O
MF
Reports
Screeners
Subscribe
Superstars
Portfolio
Watchlist
Insider Trades
Results
Data Downloader
Events Calendar
What's New
Explore
FAQs
All Features
Widgets
More
Search stocks
IND
USA
IND
IND
×
Close
IND
USA
Stocks
Futures & Options
Mutual Funds
News
Fundamentals
Reports
Corporate Actions
Alerts
Shareholding
Overview
Buy Sell Zone
F&O
Financials
News
All
News
Earnings Calls
Corporate Announcements
Research Reports
Reports
Technicals
Technicals
Price History/Seasonality
Delivery
Shareholding
Shareholding
Monthly MF Holdings
Bulk Block Deals
Insider Trading & SAST
Deals
Bulk Block Deals
Insider Trading & SAST
Corporate Actions
All
Dividend
Bonus
Split
Rights
Board Meetings
Alerts
About
Glenmark Pharmaceuticals Ltd.
NSE: GLENMARK
|
BSE: 532296
|
ISIN: INE935A01035
|
Industry: Pharmaceuticals
US FDA Approval
|
Mid-range Performer
2179.9000
10.80
(
0.50
%)
NSE
Apr 10, 2026
09:16 AM
63.17% Gain from 52W Low
Volume:
12,042
Share on Facebook
Tweet
Share on LinkedIn
Share via Whatsapp
Glenmark Pharmaceuticals Ltd.
18 Jun 2024
US FDA Approval
2179.90
0.50%
GLENMARK PHARMACEUTICALS
Hold:
Glenmark Pharmaceuticals Ltd.
by
Geojit BNP Paribas
Target: 1319
Target
Geojit BNP Paribas
Number of FII/FPI investors increased from 401 to 422 in Dec 2025 qtr.
More from Glenmark Pharmaceuticals Ltd.
Recommended
Market closes lower as Middle East tensions weaken ceasefire optimism
Trendlyne Marketwatch |
09 Apr 2026, 03:57PM
After the drop, are stock market valuations finally reasonable?
The Baseline |
09 Apr 2026, 03:18PM
Earnings Call Transcript - Q4FY20 for Glenmark Pharmaceuticals
|
29 Jun 2020